MNRI
MCID: MNN042
MIFTS: 64

Meningioma, Radiation-Induced (MNRI)

Categories: Endocrine diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Meningioma, Radiation-Induced

MalaCards integrated aliases for Meningioma, Radiation-Induced:

Name: Meningioma, Radiation-Induced 57 13
Meningioma 59 37 29 55 6 72
Radiation Induced Meningioma 53 72
Mnri 57 53
Meningioma, Benign, No Icd-O Subtype 72

Characteristics:

Orphanet epidemiological data:

59
meningioma
Prevalence: 1-9/100000 (United States),1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: All ages;

Classifications:



External Ids:

OMIM 57 606190
KEGG 37 H01556
MESH via Orphanet 45 D008579
ICD10 via Orphanet 34 D32.9
UMLS via Orphanet 73 C0025286
Orphanet 59 ORPHA2495
MedGen 42 C1853554
UMLS 72 C0025286 C1762616 C1853554

Summaries for Meningioma, Radiation-Induced

KEGG : 37
Meningiomas are the second-most common central nervous system tumor in adults. These tumors arise from arachnoid cells of the meninges, the covering layer of the brain. The majority of meningiomas tend to be benign, localized, and non-invasive. However, some meningiomas tend to be more aggressive with tendencies toward invasion of the surrounding brain, high propensity for recurrence, and in rare cases extracranial metastasis. Hereditary factors and ionizing radiation play an important role in the initiation of at least some meningiomas. Inactivation of the NF2 tumor suppressor gene is likely responsible for the initiation of more than half of all meningiomas and may cause a mesenchymal-like cytomorphology. Recently, novel mutations have been discovered in non-NF2 meningiomas. The somatic mutations in components of the SHH-GLI1 and AKT1-MTOR signaling pathways indicates the potential for cross talk of these pathways in the development of meningiomas.

MalaCards based summary : Meningioma, Radiation-Induced, also known as meningioma, is related to transitional meningioma and olfactory groove meningioma. An important gene associated with Meningioma, Radiation-Induced is NF2 (Neurofibromin 2), and among its related pathways/superpathways are MicroRNAs in cancer and Tight junction. The drugs Thrombin and Hemostatics have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and pituitary, and related phenotypes are chromosomal breakage induced by ionizing radiation and increased sensitivity to ionizing radiation

More information from OMIM: 606190

Related Diseases for Meningioma, Radiation-Induced

Diseases related to Meningioma, Radiation-Induced via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1117)
# Related Disease Score Top Affiliating Genes
1 transitional meningioma 34.6 NF2 MUC1
2 olfactory groove meningioma 34.4 PGR NF2
3 intraventricular meningioma 34.4 NF2 GFAP
4 cerebral convexity meningioma 34.2 NF2 GFAP
5 rhabdoid meningioma 34.2 VIM SMARCB1 NF2 GFAP
6 benign meningioma 34.1 PGR NF2 MKI67 EPB41L3
7 fibrous meningioma 34.1 VIM S100B NF2 MUC1
8 clear cell meningioma 33.9 VIM PGR MUC1 GFAP
9 chordoid meningioma 33.8 VIM S100B MUC1 GFAP
10 suprasellar meningioma 33.8 PGR GFAP
11 hemangiopericytoma, malignant 33.7 VIM S100B MUC1
12 schwannomatosis 1 33.4 SMARCB1 NF2
13 neurofibromatosis, type ii 32.8 RDX NF2 MSN EZR EPB41L3
14 monosomy 22 32.0 SMARCB1 NF2
15 endometriosis 31.9 PGR MIR200A H19
16 secretory meningioma 31.7 VIM MUC1
17 neurofibroma 31.5 S100B NF2 MUC1
18 neuroma 31.1 SMARCB1 S100B NF2 GFAP
19 cavernous hemangioma 31.0 VIM MUC1 MKI67
20 cerebellopontine angle tumor 30.9 SMARCB1 NF2 GFAP
21 brain cancer 30.9 SMARCB1 PDGFB NF2 GFAP
22 rhabdoid tumor predisposition syndrome 1 30.9 VIM SMARCB1 MUC1
23 spindle cell sarcoma 30.9 VIM S100B NF2 MUC1
24 non-functioning pituitary adenoma 30.8 S100B MUC1
25 oligodendroglioma 30.8 S100B PDGFB GFAP
26 mesothelioma, malignant 30.8 VIM NF2 MUC1
27 benign ependymoma 30.8 NF2 GFAP EPB41L3
28 papilloma of choroid plexus 30.7 S100B MUC1 GFAP
29 ganglioglioma 30.7 SMARCB1 S100B GFAP
30 chordoma 30.7 VIM SMARCB1 S100B MUC1 GFAP
31 hemangioblastoma 30.7 S100B MUC1 GFAP EZR
32 medulloblastoma 30.6 SUFU SMARCB1 S100B PDGFB H19 GFAP
33 perineurioma 30.6 VIM S100B MUC1
34 pathologic nystagmus 30.6 RDX MSN EZR
35 leiomyosarcoma 30.6 VIM S100B PGR
36 spinal cord ependymoma 30.6 NF2 EPB41L3
37 optic nerve glioma 30.6 VIM S100B MUC1 GFAP
38 clear cell ependymoma 30.5 VIM MUC1 GFAP
39 dermoid cyst 30.5 VIM PGR MUC1
40 carcinosarcoma 30.4 VIM PGR MUC1
41 neurilemmoma 30.4 VIM SMARCB1 S100B NF2 MSN GFAP
42 dermatofibrosarcoma protuberans 30.4 VIM S100B PDGFB
43 pancreatic neuroendocrine tumor 30.4 MKI67 MEG3
44 gliosarcoma 30.4 VIM S100B GFAP
45 malignant fibroxanthoma 30.3 VIM S100B MUC1 MKI67
46 nervous system cancer 30.3 SMARCB1 NF2 GFAP
47 wilms tumor 1 30.3 SMARCB1 PGR MEG3 H19
48 leiomyoma 30.3 VIM PGR MKI67
49 retroperitoneal leiomyosarcoma 30.2 SMARCB1 PGR
50 cutaneous fibrous histiocytoma 30.2 VIM S100B PDGFB

Graphical network of the top 20 diseases related to Meningioma, Radiation-Induced:



Diseases related to Meningioma, Radiation-Induced

Symptoms & Phenotypes for Meningioma, Radiation-Induced

Human phenotypes related to Meningioma, Radiation-Induced:

59 32 (show top 50) (show all 75)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 chromosomal breakage induced by ionizing radiation 59 32 hallmark (90%) Very frequent (99-80%) HP:0010997
2 increased sensitivity to ionizing radiation 59 32 hallmark (90%) Very frequent (99-80%) HP:0011133
3 intracranial meningioma 59 32 hallmark (90%) Very frequent (99-80%) HP:0100009
4 nausea and vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002017
5 hypogonadotrophic hypogonadism 59 32 frequent (33%) Frequent (79-30%) HP:0000044
6 headache 59 32 frequent (33%) Frequent (79-30%) HP:0002315
7 focal-onset seizure 59 32 frequent (33%) Frequent (79-30%) HP:0007359
8 secondary growth hormone deficiency 59 32 frequent (33%) Frequent (79-30%) HP:0008240
9 impotence 59 32 frequent (33%) Frequent (79-30%) HP:0000802
10 decreased circulating cortisol level 59 32 frequent (33%) Frequent (79-30%) HP:0008163
11 decreased serum estradiol 59 32 frequent (33%) Frequent (79-30%) HP:0008214
12 amenorrhea 59 32 frequent (33%) Frequent (79-30%) HP:0000141
13 pituitary hypothyroidism 59 32 frequent (33%) Frequent (79-30%) HP:0008245
14 decreased circulating acth level 59 32 frequent (33%) Frequent (79-30%) HP:0002920
15 bitemporal hemianopia 59 32 frequent (33%) Frequent (79-30%) HP:0030521
16 prolactin excess 59 32 frequent (33%) Frequent (79-30%) HP:0000870
17 abnormal brain fdg positron emission tomography 59 32 frequent (33%) Frequent (79-30%) HP:0012658
18 focal t2 hypointense thalamic lesion 59 32 frequent (33%) Frequent (79-30%) HP:0012691
19 decreased circulating follicle stimulating hormone level 59 32 frequent (33%) Frequent (79-30%) HP:0030341
20 decreased circulating luteinizing hormone level 59 32 frequent (33%) Frequent (79-30%) HP:0030344
21 decreased serum testosterone level 32 frequent (33%) HP:0040171
22 obesity 59 32 occasional (7.5%) Occasional (29-5%) HP:0001513
23 hydrocephalus 59 32 occasional (7.5%) Occasional (29-5%) HP:0000238
24 ataxia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001251
25 facial palsy 59 32 occasional (7.5%) Occasional (29-5%) HP:0010628
26 increased intracranial pressure 59 32 occasional (7.5%) Occasional (29-5%) HP:0002516
27 ophthalmoplegia 59 32 occasional (7.5%) Occasional (29-5%) HP:0000602
28 papilledema 59 32 occasional (7.5%) Occasional (29-5%) HP:0001085
29 difficulty walking 59 32 occasional (7.5%) Occasional (29-5%) HP:0002355
30 slow decrease in visual acuity 59 32 occasional (7.5%) Occasional (29-5%) HP:0007924
31 abnormality of the sense of smell 59 32 occasional (7.5%) Occasional (29-5%) HP:0004408
32 abnormal cerebellum morphology 59 32 occasional (7.5%) Occasional (29-5%) HP:0001317
33 upper limb muscle weakness 59 32 occasional (7.5%) Occasional (29-5%) HP:0003484
34 lower limb muscle weakness 59 32 occasional (7.5%) Occasional (29-5%) HP:0007340
35 neurofibromas 59 32 occasional (7.5%) Occasional (29-5%) HP:0001067
36 hemiparesis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001269
37 abnormal kinetic perimetry test 59 32 occasional (7.5%) Occasional (29-5%) HP:0030591
38 oculomotor nerve palsy 59 32 occasional (7.5%) Occasional (29-5%) HP:0012246
39 weak extraocular muscles 59 32 occasional (7.5%) Occasional (29-5%) HP:0007715
40 prolactin deficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0008202
41 hypothalamic hypothyroidism 59 32 occasional (7.5%) Occasional (29-5%) HP:0008237
42 abnormality of central sensory function 59 32 occasional (7.5%) Occasional (29-5%) HP:0011730
43 neoplasm of the anterior pituitary 59 32 occasional (7.5%) Occasional (29-5%) HP:0011750
44 enlarged pituitary gland 59 32 occasional (7.5%) Occasional (29-5%) HP:0012505
45 visual acuity test abnormality 59 32 occasional (7.5%) Occasional (29-5%) HP:0030532
46 spinal meningioma 59 32 occasional (7.5%) Occasional (29-5%) HP:0100010
47 trigeminal neuralgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0100661
48 emotional lability 59 32 very rare (1%) Very rare (<4-1%) HP:0000712
49 neurological speech impairment 59 32 very rare (1%) Very rare (<4-1%) HP:0002167
50 blindness 59 32 very rare (1%) Very rare (<4-1%) HP:0000618

Clinical features from OMIM:

606190

GenomeRNAi Phenotypes related to Meningioma, Radiation-Induced according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 SMARCB1

MGI Mouse Phenotypes related to Meningioma, Radiation-Induced:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.85 EPB41L3 GFAP MN1 NF2 NOS2 PGR
2 mortality/aging MP:0010768 9.73 EPB41L3 EZR GFAP MN1 NF2 NOS2
3 neoplasm MP:0002006 9.17 EPB41L3 MN1 NF2 NOS2 PGR SMARCB1

Drugs & Therapeutics for Meningioma, Radiation-Induced

Drugs for Meningioma, Radiation-Induced (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 258)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2 Hemostatics Phase 4
3 Coagulants Phase 4
4 Fibrin Tissue Adhesive Phase 4
5
Tranexamic Acid Approved Phase 3 1197-18-8 5526
6
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
7
Donepezil Approved Phase 3 120014-06-4 3152
8
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
9
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
10
Ondansetron Approved Phase 3 99614-02-5 4595
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Cisatracurium Approved Phase 3 96946-41-7
13
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
14
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
15
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
16
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
17
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
18
Histamine Approved, Investigational Phase 3 51-45-6 774
19
Cyproheptadine Approved Phase 3 129-03-3 2913
20
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
21 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
22 Antifibrinolytic Agents Phase 3
23 Progestins Phase 3
24 Peripheral Nervous System Agents Phase 3
25 Cholinesterase Inhibitors Phase 3
26 Cholinergic Agents Phase 3
27 Nootropic Agents Phase 3
28 Liver Extracts Phase 3
29 Emetics Phase 3
30 Cola Phase 3
31 Anesthetics, Intravenous Phase 3
32 Narcotics Phase 3
33 Analgesics, Opioid Phase 3
34 Adjuvants, Anesthesia Phase 3
35 Anesthetics, General Phase 3
36 Analgesics Phase 3
37 Tocolytic Agents Phase 3
38 Central Nervous System Depressants Phase 3
39 Antihypertensive Agents Phase 3
40 Anesthetics Phase 3
41 Anti-Arrhythmia Agents Phase 3
42 Anticonvulsants Phase 3
43 Vasoconstrictor Agents Phase 3
44 calcium channel blockers Phase 3
45 Calcium, Dietary Phase 3
46 Gastrointestinal Agents Phase 3
47 Central Nervous System Stimulants Phase 3
48 Neurotransmitter Agents Phase 3
49 Dermatologic Agents Phase 3
50 Dexmethylphenidate Hydrochloride Phase 3

Interventional clinical trials:

(show top 50) (show all 189)
# Name Status NCT ID Phase Drugs
1 Neurocognitive Outcome Assessment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Unknown status NCT03190122 Phase 4
2 Dissection of the Outer Layer of the Lateral Wall of the Cavernous Sinus Decreases Bleeding as Compared to Direct Tumor Attack in Middle Fossa Meningiomas: A Randomized Controlled Trial Unknown status NCT02863484 Phase 4
3 A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery Completed NCT02034799 Phase 4
4 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
5 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
6 Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma Completed NCT03015701 Phase 3 Mifepristone
7 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
8 Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE Completed NCT02947984 Phase 3
9 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
10 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
11 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Recruiting NCT03180268 Phase 3
12 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Not yet recruiting NCT03558516 Phase 3 Magnesium group;Normal saline group
13 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
14 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
15 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma Unknown status NCT00006119 Phase 2 hydroxyurea
17 IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
18 Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas. Unknown status NCT02333565 Phase 2 Everolimus;Octreotide
19 Feasibility and Phase II Study Using Proton Radiation For WHO Grade I-III Meningiomas and Hemangiopericytomas Unknown status NCT01117844 Phase 1, Phase 2
20 Proton Radiation for Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
21 Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group Completed NCT02234050 Phase 2 Trabectedin
22 Phase II Study of Hydroxyurea for Unresectable Meningioma Completed NCT00003590 Phase 2 hydroxyurea
23 A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas Completed NCT00348790 Phase 2 vatalanib
24 Adjuvant Postoperative High-Dose Radiotherapy for Atypical and Malignant Meningioma: a Phase-II and Observation Study Completed NCT00626730 Phase 2
25 Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma Completed NCT00859040 Phase 2 SOM230C
26 A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma Completed NCT00354913 Phase 2 hydroxyurea;imatinib mesylate
27 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
28 Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
29 A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue Completed NCT01032200 Phase 2 Armodafinil
30 Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
31 Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study. Completed NCT00629889 Phase 2 levetiracetam;pregabalin
32 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
33 A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors Completed NCT00006102 Phase 2 becatecarin
34 Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy Completed NCT00005955 Phase 2 temozolomide
35 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
36 A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas Completed NCT00004868 Phase 1, Phase 2 semaxanib
37 Phase I Study of At-Labeled Anti-Tenascin Human/Mouse Chimeric Monoclonal Antibody 81C6 (ch81C6) Via Surgically Created Cystic Resection Cavity in the Treatment of Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
38 Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases Completed NCT00070161 Phase 2 donepezil hydrochloride
39 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
40 Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas Completed NCT00002965 Phase 2
41 Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
42 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
43 Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma Recruiting NCT03279692 Phase 2 Pembrolizumab
44 A Single Arm, Open-label, Multicenter Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma Recruiting NCT03971461 Phase 2 Lutathera
45 An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma Recruiting NCT02648997 Phase 2 Nivolumab - 240 mg;Ipilimumab - 3 mg/kg;Nivolumab - 480 mg;Nivolumab - 1 mg/kg
46 A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma Recruiting NCT03016091 Phase 2 Pembrolizumab
47 A Single Arm Phase II Study Of The Dual mTORC1/mTORC2 Inhibitor Vistusertib (AZD2014) Provided On An Intermittent Schedule For Sporadic Patients With Grade II-III Meningiomas That Recur Or Progress After Surgery And Radiation Recruiting NCT03071874 Phase 2 AZD2014
48 Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial Recruiting NCT03936426 Phase 1, Phase 2 Cu-64 SARTATE and Cu-67 SARTATE
49 Effect of Hippocampal Sparing on Neurocognitive Functions and Quality of Live in Patients Irradiated in the Neurocranial Area Recruiting NCT01849484 Phase 2
50 A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma Recruiting NCT03604978 Phase 1, Phase 2

Search NIH Clinical Center for Meningioma, Radiation-Induced

Genetic Tests for Meningioma, Radiation-Induced

Genetic tests related to Meningioma, Radiation-Induced:

# Genetic test Affiliating Genes
1 Meningioma 29

Anatomical Context for Meningioma, Radiation-Induced

MalaCards organs/tissues related to Meningioma, Radiation-Induced:

41
Brain, Bone, Pituitary, Spinal Cord, Breast, Lung, Pineal

Publications for Meningioma, Radiation-Induced

Articles related to Meningioma, Radiation-Induced:

(show top 50) (show all 13903)
# Title Authors PMID Year
1
Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. 9 38 71
8162072 1994
2
Deletion of Alu sequences in the fifth c-sis intron in individuals with meningiomas. 9 38 71
2212004 1990
3
A novel germline mutation of PTEN associated with brain tumours of multiple lineages. 38 71
12085208 2002
4
Somatic mutations in the neurofibromatosis type 2 gene in sporadic meningiomas. 38 71
7868131 1995
5
Chromosome translocation t(14;22) and oncogene (c-sis) variant in a pedigree with familial meningioma. 38 71
3969118 1985
6
Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. 38 88
19703993 2009
7
Cytogenetic study of six cases of radiation-induced meningiomas. 8
11376799 2001
8
A point mutation in the last intron responsible for increased expression and transforming activity of the c-Ha-ras oncogene. 71
3133569 1988
9
Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. 9 38
19922547 2010
10
Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. 9 38
19747051 2010
11
Expression of podoplanin and calretinin in meningioma: an immunohistochemical study. 9 38
20425044 2010
12
Development of a predictor for human brain tumors based on gene expression values obtained from two types of microarray technologies. 9 38
20235875 2010
13
Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II. 9 38
20054806 2010
14
Immunohistochemical expression of aromatase and estrogen, androgen and progesterone receptors in normal and neoplastic human meningeal cells. 9 38
19703265 2010
15
Genomic deletions at 1p and 14q are associated with an abnormal cDNA microarray gene expression pattern in meningiomas but not in schwannomas. 9 38
19963129 2010
16
Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype. 9 38
19885562 2009
17
Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas. 9 38
19429976 2009
18
Diffuse craniospinal metastases of intraventricular rhabdoid papillary meningioma with glial fibrillary acidic protein expression: a case report. 9 38
19482417 2009
19
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. 9 38
19451225 2009
20
Distinguishing chordoid meningiomas from their histologic mimics: an immunohistochemical evaluation. 9 38
19194275 2009
21
[Immunohistochemical expression of progesterone receptor in relationship with histological grade and risk of relapses in intracranial meningiomas]. 9 38
19603293 2009
22
Meningioma in untreated congenital adrenal hyperplasia: a relationship? 9 38
19039522 2009
23
Immunohistochemical comparison of chordoma with chondrosarcoma, myxopapillary ependymoma, and chordoid meningioma. 9 38
19521276 2009
24
The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. 9 38
18953429 2008
25
Paraneoplastic acanthosis nigricans and silent meningioma producing transforming growth factor-alpha. 9 38
19049942 2008
26
Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry. 9 38
18778186 2008
27
MN1 affects expression of genes involved in hematopoiesis and can enhance as well as inhibit RAR/RXR-induced gene expression. 9 38
18632758 2008
28
Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. 9 38
18808065 2008
29
Cyclin D1 immunoreactivity in meningiomas. 9 38
18379871 2008
30
Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. 9 38
18418552 2008
31
BCR expression is decreased in meningiomas showing loss of heterozygosity of 22q within a new minimal deletion region. 9 38
18474292 2008
32
Sex steroid and epidermal growth factor profile of giant meningiomas associated with pregnancy. 9 38
17707480 2008
33
Multiple intracranial meningiomas causing papilledema and visual loss in a patient with nevoid Basal cell carcinoma syndrome. 9 38
18347458 2008
34
Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. 9 38
17962031 2008
35
Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. 9 38
17924978 2008
36
Specific genes expressed in association with progesterone receptors in meningioma. 9 38
18172325 2008
37
Periosteal osteoblastoma of the calvaria mimicking a meningioma. 9 38
18359169 2008
38
RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. 9 38
17912429 2007
39
Merlin expression in secretory meningiomas: evidence of an NF2-independent pathogenesis? Immunohistochemical study. 9 38
17721284 2007
40
Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. 9 38
17785665 2007
41
Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A. 9 38
17695396 2007
42
Molecular genetics of meningiomas: from basic research to potential clinical applications. 9 38
17460514 2007
43
The astrocytic response towards invasive meningiomas. 9 38
17359357 2007
44
Establishment of an in vivo meningioma model with human telomerase reverse transcriptase. 9 38
17415213 2007
45
Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors. 9 38
17225937 2007
46
NF2 gene expression in sporadic meningiomas: relation to grades or histotypes real time-pCR study. 9 38
17319281 2007
47
New immunohistochemical markers in the evaluation of central nervous system tumors: a review of 7 selected adult and pediatric brain tumors. 9 38
17284108 2007
48
Overexpression of midkine contributes to anti-apoptotic effects in human meningiomas. 9 38
17181554 2007
49
Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas? 9 38
17961045 2007
50
Histological classification and molecular genetics of meningiomas. 9 38
17110285 2006

Variations for Meningioma, Radiation-Induced

ClinVar genetic disease variations for Meningioma, Radiation-Induced:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 NF2 NM_000268.3(NF2): c.995del (p.Lys332fs) deletion Pathogenic rs587776563 22:30064431-30064431 22:29668442-29668442
2 NF2 NM_000268.3(NF2): c.169C> T (p.Arg57Ter) single nucleotide variant Pathogenic rs121434259 22:30032794-30032794 22:29636805-29636805
3 PDGFB PDGFB, 135-BP DEL, IVS5 deletion Pathogenic
4 t(5;22)(q31.2;q12.1) Translocation Likely pathogenic 22:28192751--1 :0-0
5 DNMT1 NM_001130823.3(DNMT1): c.1645-1G> T single nucleotide variant Likely pathogenic 19:10265450-10265450 19:10154774-10154774
6 PTEN NM_000314.7(PTEN): c.701G> A (p.Arg234Gln) single nucleotide variant Uncertain significance rs121909235 10:89717676-89717676 10:87957919-87957919

Copy number variations for Meningioma, Radiation-Induced from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 81307 14 101400000 103200000 Loss Meningioma
2 109410 17 25800000 38100000 Copy number HER-2 Meningioma
3 116388 17 6500000 10700000 Copy number TP53 Meningioma

Expression for Meningioma, Radiation-Induced

Search GEO for disease gene expression data for Meningioma, Radiation-Induced.

Pathways for Meningioma, Radiation-Induced

GO Terms for Meningioma, Radiation-Induced

Cellular components related to Meningioma, Radiation-Induced according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cell projection GO:0042995 9.97 VIM RDX NF2 MSN GFAP EZR
2 apical plasma membrane GO:0016324 9.81 RDX MUC1 MSN EZR
3 cell body GO:0044297 9.63 NF2 GFAP EZR
4 microvillus GO:0005902 9.54 RDX MSN EZR
5 cell periphery GO:0071944 9.5 RDX MSN EZR
6 uropod GO:0001931 9.48 MSN EZR
7 ruffle GO:0001726 9.46 S100B RDX NF2 EZR
8 invadopodium GO:0071437 9.43 MSN EZR
9 astrocyte projection GO:0097449 9.4 GFAP EZR
10 cell tip GO:0051286 9.26 RDX EZR
11 apical part of cell GO:0045177 9.26 RDX NF2 MSN EZR
12 filopodium GO:0030175 8.92 RDX NF2 MSN EZR

Biological processes related to Meningioma, Radiation-Induced according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.91 VIM RDX PDGFB MSN EZR
2 regulation of cell shape GO:0008360 9.65 S100B RDX MSN EZR EPB41L3
3 intermediate filament organization GO:0045109 9.59 VIM GFAP
4 microvillus assembly GO:0030033 9.58 RDX EZR
5 astrocyte development GO:0014002 9.58 VIM GFAP
6 regulation of cell size GO:0008361 9.58 RDX MSN EZR
7 establishment of epithelial cell apical/basal polarity GO:0045198 9.57 MSN EZR
8 protein kinase A signaling GO:0010737 9.56 RDX EZR
9 cytoskeletal anchoring at plasma membrane GO:0007016 9.55 EZR EPB41L3
10 gland morphogenesis GO:0022612 9.54 MSN EZR
11 establishment of endothelial barrier GO:0061028 9.54 RDX MSN EZR
12 Bergmann glial cell differentiation GO:0060020 9.52 VIM GFAP
13 positive regulation of cellular protein catabolic process GO:1903364 9.5 RDX MSN EZR
14 paracrine signaling GO:0038001 9.49 PGR PDGFB
15 positive regulation of histone H4 acetylation GO:0090240 9.48 SMARCB1 MUC1
16 membrane to membrane docking GO:0022614 9.46 MSN EZR
17 intermediate filament-based process GO:0045103 9.43 VIM GFAP
18 positive regulation of early endosome to late endosome transport GO:2000643 9.33 RDX MSN EZR
19 positive regulation of protein localization to early endosome GO:1902966 9.13 RDX MSN EZR
20 regulation of organelle assembly GO:1902115 8.8 RDX MSN EZR

Molecular functions related to Meningioma, Radiation-Induced according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 actin binding GO:0003779 9.55 RDX NF2 MSN EZR EPB41L3
2 ATPase binding GO:0051117 9.43 RDX PGR EZR
3 S100 protein binding GO:0044548 9.32 S100B EZR
4 structural constituent of cytoskeleton GO:0005200 9.26 VIM MSN GFAP EPB41L3
5 cytoskeletal protein binding GO:0008092 9.02 RDX NF2 MSN EZR EPB41L3

Sources for Meningioma, Radiation-Induced

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....